Is China Back?

By Peter Rosenstreich
Published on 17.05.2024

The Chinese stock market has been a subject of much debate, and it's essential to consider its investment potential. Many people view China's economy as chaotic due to geopolitical tensions and strict regulations. This has resulted in Chinese stocks being underrepresented in global portfolios, leading to differences in value compared to other markets. In 2024, China's equity markets experienced significant shifts. In January, Chinese stocks on the Shanghai and Shenzhen Stock Exchanges and Hong Kong and US-listed China ADRs dropped due to low investor positioning in China equities. As Hong Kong and Mainland China benchmarks reached key index levels, index futures were liquidated, leading to market declines. But conditions for appreciation have materialized. Since February, Chinese benchmarks have been up 15-20%.

Several factors have driven this strong rally.

The Chinese government is buying Mainland stocks to stabilize the domestic market and influence stock market indices. Unlike many developed markets, China does not have market circuit breakers to halt trading during periods of volatility. Therefore, government-related entities act as buyers of last resort. This time, China is being more public about its stock purchases.

International sentiment towards Chinese stocks has started to improve, with more investors turning positive and managers' underweight China positions showing signs of change. Investors' neutral or underweight positions influenced the decline in Chinese equities in January. US investors were the first to reduce their China positions due to trade tensions and regulatory issues. European investors followed suit after geopolitical uncertainty from Russia's invasion of Ukraine, while Asian and local Chinese investors divested from Mainland stocks later.
On April 12, The State Council issued "9 Key Points" to enhance China's capital markets, a rare move for China's top political body.

The measures include:

Controlling the supply of IPOs.
Promoting dividends and corporate governance improvements.
Encouraging bank and trust products to allocate more to equities.

Some investors have not recognized this despite attractive valuations in China equities. However, many companies, particularly in the internet sector, are addressing this by buying back their stock.

Several other positive developments are contributing to the strong performance of Chinese stocks this year:

China's macroeconomic data has surpassed expectations, with PMIs, GDP growth, and exports performing better than anticipated, indicating more resilient growth.

China has shifted away from restrictive policies towards a pro-growth and pro-markets stance, with significant monetary easing, rate cuts, and plans for shareholder-friendly reforms, as well as interventions in the market by China's sovereign wealth fund.

Despite negative headlines, a closer look at China's fundamentals reveals a remarkably resilient economy. It's showing accelerating corporate profits, decisive policy action, and tepid improvements in sentiment. The significant underweighting of Chinese stocks by investors this year, despite their strong performance, has likely impacted their overall performance. This underscores the importance of looking beyond the perception of the Chinese market and staying anchored in fundamentals rather than being swayed by headlines.

Follow us
Be in the know

Sign up to our newsletter and receive a monthly selection right in your inbox


Sponsors
UEFA Europa LeagueGenève ServetteZSC Lions

General Information
This website is operated jointly by Swissquote MEA Ltd. (“SQMEA”) and Swissquote Bank SA’s Representative Office in Dubai (the “Swissquote Representative Office”). SQMEA is incorporated in the Dubai International Financial Centre (“DIFC”) and regulated by the Dubai Financial Services Authority (“DFSA”). The Swissquote Representative Office is licensed by the Central Bank of the United Arab Emirates to carry out representative office activities only. Swissquote Bank SA (“SQB”) is incorporated in Switzerland and regulated by the Swiss Financial Market Supervisory Authority (FINMA).
 
Depending on the section of the website, products and services presented may be promoted by SQMEA or by the Swissquote Representative Office. In particular, SQMEA does not promote, arrange or offer to Retail Clients access to any services relating to contracts for differences (CFDs), rolling spot foreign exchange, or other Restricted Speculative Investments, as defined in the DFSA Rulebook (www.dfsa.ae).
 
SQMEA operates multiple business lines. For the target audience of this website, all products and services presented are offered by SQB.
 
No Offer or Advice
The content of this website is provided for information purposes only and does not constitute investment advice, a recommendation, a solicitation, or an offer to buy or sell any financial instruments.
Nothing on this website should be relied upon as the sole basis for making investment decisions. Visitors should seek independent financial, legal, and tax advice before making any investment.
 
Product Availability and Eligibility
Access to products and services described on this website is subject to applicable laws, regulations, and eligibility requirements.
Certain products or services may not be available in all jurisdictions or to all clients, and additional conditions or restrictions may apply.
 
Risk Warning
Investing in financial instruments involves risk, including the possible loss of capital. Past performance is not a reliable indicator of future results.
Further information is available in the “Risks Involved in Trading Financial Instruments” disclosure.
 
AI-Generated Content
Some visual or editorial content on this website may be generated or enhanced using artificial intelligence (AI) tools.
All such content is subject to human review and approval to ensure accuracy, appropriateness, and compliance with applicable regulatory requirements. AI is not used to provide personalised investment advice, suitability assessments, or client-specific recommendations.